At low nanomolar concentrations, the synthetic A3 AR agonist 21 also inhibits the growth of HCT-116 human colon carcinoma cells, a response reversible by the selective A3 AR antagonist MRS1523 (24). Here, ADORA3 is linked to colon carcinoma.